Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Gijs van de Wetering"'
Autor:
Anuja Chatterjee, Gijs van de Wetering, Ron Goeree, Carolyn Owen, Anne Marie Desbois, Stephane Barakat, Beenish S. Manzoor, Kavita Sail
Publikováno v:
PharmacoEconomics - Open. 7:199-216
Venetoclax is a first-in-class targeted therapy option that is an inducer of apoptosis in chronic lymphocytic leukemia (CLL) cells. The open-label phase III CLL14 clinical trial showed that venetoclax combined with obinutuzumab (VEN+O) is superior to
Autor:
Gilles Salles, Anthony Wang, Alex Mutebi, Abualbishr Alshreef, Kalatu R. Davies, Gijs van de Wetering, Viktor Chirikov
Publikováno v:
Blood. 140:10934-10935
Autor:
Xavier Muñoz-Gall, Gijs van de Wetering, Shibing Yang, Andrea García, José Luis Izquierdo-Alonso, Francisco-Javier González-Barcala, Esther Mariscal
Publikováno v:
Scientia
Asma eosinofílica greu; Comparació indirecta del tractament; Mepolizumab Severe eosinophilic asthma; Indirect treatment comparison; Mepolizumab Asma eosinofílica severa; Comparación de tratamiento indirecto; Mepolizumab Aim To analyse the cost-ef
Existing treatment-sequence models for psoriasis are limited by lines of treatments included. We sought to more accurately capture the patient experience with an increasing number of treatments while maintaining the complexity and transparency of cur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca550f4b717e10d97c7156662f326a57
Autor:
Arliene Ravelo, Kavita Sail, Beenish S Manzoor, Gijs van de Wetering, Venetia Qendri, Anuja Chatterjee, Sheila Shapouri, Matthew S. Davids
Publikováno v:
Journal of managed carespecialty pharmacy. 27(11)
BACKGROUND: Chronic lymphocytic leukemia (CLL) is a significant health and economic burden in the United States. Treatments include chemoimmunotherapy, such as obinutuzumab (G) plus chlorambucil (Clb) or bendamustine plus rituximab (BR), and chemothe
Autor:
Beenish S Manzoor, Patricia Manzi, Gijs van de Wetering, Anne Marie Desbois, Kavita Sail, Ron Goeree, Carolyn Owen, Anuja Chatterjee
Publikováno v:
Blood. 136:31-32
OBJECTIVES: To estimate the cost-effectiveness of venetoclax + obinutuzumab (GAZYVA®, G), (VEN+G) in the treatment of first-line (1L) chronic lymphocytic leukemia (CLL) from a Canadian health care system cost perspective. METHODS: A three-state part
Autor:
Todd M. Zimmerman, Keri Yang, Boxiong Tang, Rongzhe Liu, Qian Zhao, Gijs van de Wetering, Jorge J. Castillo, Yu Wang, Xin Gao, Aileen Cohen
Publikováno v:
Journal of Clinical Oncology. 39:e18856-e18856
e18856 Background: The efficacy of zanubrutinib and ibrutinib was examined in the randomized ASPEN trial (NCT03053440) in adult patients with Waldenström macroglobulinemia (WM). This analysis assessed the cost-effectiveness (CE) of zanubrutinib vs i
Autor:
Sheila Shapouri, Arliene Ravelo, Kavita Sail, Beenish S Manzoor, Gijs van de Wetering, Matthew S. Davids, Anuja Chatterjee, Michael Hallek
Publikováno v:
Blood. 134:4741-4741
INTRODUCTION: Historically chemoimmunotherapy has been the standard of care in the treatment of first-line (1L) chronic lymphocytic leukemia (CLL). More recently several effective oral targeted agents, such as ibrutinib-based regimens, have provided
Autor:
Eddy M. M. Adang, Mireille J. M. Broeders, Willem Woertman, André L. M. Verbeek, Gijs van de Wetering
Publikováno v:
European Journal of Health Economics, 14, 911-8
European Journal of Health Economics, 14, 6, pp. 911-8
European Journal of Health Economics, 14, 6, pp. 911-8
Item does not contain fulltext This paper examines the short run inefficiencies that arise during gradual implementation of a new cost-effective technology in healthcare. These inefficiencies arise when health gains associated with the new technology
Autor:
Arun Krishna, Istvan M. Majer, Gijs van de Wetering, Anuja Roy, Elisabeth Gray, Zoltan Polanyi
Publikováno v:
Applied health economics and health policy. 15(1)
In the UK, the standard of care for patients with multiple myeloma who received ≥2 prior treatments is lenalidomide plus dexamethasone (LEN + DEX) and pomalidomide plus DEX (POM + DEX) (in Wales only). Recently, panobinostat plus bortezomib and DEX